Dabigatran etexilate and risk of myocardial infarction, other cardiovascular events, major bleeding, and all-cause mortality: a systematic review and meta-analysis of randomized controlled trials

Douxfils J, Buckinx F, Mullier F, Minet V, Rabenda V, Reginster JY, Hainaut P, Bruyere O, Dogne JM

Record Status
This is a systematic review that meets the criteria for inclusion on DARE. If you would like us to consider prioritising the writing of a critical abstract for this review please e-mail CRD-DARE@york.ac.uk quoting the Accession Number of this record. Please note that priority is given to fast track requests from the UK National Health Service.

Bibliographic details

PubMedID
24906369

DOI
10.1161/JAHA.113.000515

Indexing Status
Subject indexing assigned by NLM

MeSH
Benzimidazoles /adverse effects /therapeutic use; Cardiovascular Diseases /chemically induced; Dabigatran; Factor Xa Inhibitors /adverse effects /therapeutic use; Hemorrhage /chemically induced; Humans; Mortality; Myocardial Infarction /chemically induced; Pyridines /adverse effects /therapeutic use; Randomized Controlled Trials as Topic; Risk Factors; Venous Thromboembolism /prevention & control

AccessionNumber
12014038682

Date bibliographic record published
09/10/2014